Citation: | LIU Zengwei, CHEN Pinru, LI Huiru, CHEN Hua, XIE Zhien, FANG Weijun. Clinical and CT imaging features of Mycobacterium kansasii pulmonary disease[J]. Journal of Molecular Imaging, 2024, 47(3): 321-326. doi: 10.12122/j.issn.1674-4500.2024.03.16 |
[1] |
Johnston JC, Chiang L, Elwood K. Mycobacterium kansasii[J]. Microbiol Spectr, 2017, 5(1). doi: 10.1128/microbiolspec.TNMI7-0011-2016.
|
[2] |
Wang J, McIntosh F, Radomski N, et al. Insights on the emergence of Mycobacterium tuberculosis from the analysis of Mycobacterium kansasii[J]. Genome Biol Evol, 2015, 7(3): 856-70. doi: 10.1093/gbe/evv035
|
[3] |
Buhler VB, Pollak A. Human infection with atypical acid‑fast organisms: report of two cases with pathologic findings[J]. Am J Clin Pathol, 1953, 23(4): 363-74. doi: 10.1093/ajcp/23.4.363
|
[4] |
Baldwin SL, Larsen SE, Ordway D, et al. The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases[J]. PLoS Neglected Trop Dis, 2019, 13(2): e0007083. doi: 10.1371/journal.pntd.0007083
|
[5] |
Brode SK, Daley CL, Marras TK. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review[J]. Int J Tuberc Lung Dis, 2014, 18(11): 1370-7. doi: 10.5588/ijtld.14.0120
|
[6] |
Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria[J]. Clin Microbiol Rev, 1996, 9(2): 177-215. doi: 10.1128/CMR.9.2.177
|
[7] |
中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版)[J]. 中华结核和呼吸杂志, 2020, 43(11): 918-46. doi: 10.3760/cma.j.cn112147-20200508-00570
|
[8] |
Zweijpfenning S, Hoefsloot W, Ingen J. Geographic distribution of nontuberculous mycobacteria isolated from clinical specimens: a systematic review[J]. Semin Respir Crit Care Med, 2018, 39(3): 336-42. doi: 10.1055/s-0038-1660864
|
[9] |
Wu J, Zhang YY, Li J, et al. Increase in nontuberculous mycobacteria isolated in Shanghai, China: results from a population-based study[J]. PLoS One, 2014, 9(10): e109736. doi: 10.1371/journal.pone.0109736
|
[10] |
Hoefsloot W, van Ingen J, Andrejak C, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study[J]. Eur Respir J, 2013, 42(6): 1604-13. doi: 10.1183/09031936.00149212
|
[11] |
陈华, 胡锦兴, 陈品儒, 等. 广州市非结核分枝杆菌流行状况与菌种分布特征: 基于2018-2019年数据[J]. 分子影像学杂志, 2021, 44(2): 378-82. https://www.cnki.com.cn/Article/CJFDTOTAL-FZYX202102032.htm
|
[12] |
Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria[J]. Clin Chest Med, 2015, 36(1): 13-34. doi: 10.1016/j.ccm.2014.10.002
|
[13] |
Ehsani L, Reddy SC, Mosunjac M, et al. Fatal aortic pseudoaneurysm from disseminated Mycobacterium kansasii infection: case report[J]. Hum Pathol, 2015, 46(3): 467-70. doi: 10.1016/j.humpath.2014.11.005
|
[14] |
Matveychuk A, Fuks L, Priess R, et al. Clinical and radiological features of Mycobacterium kansasii and other NTM infections[J]. Respir Med, 2012, 106(10): 1472-7. doi: 10.1016/j.rmed.2012.06.023
|
[15] |
Akram SM, Rawla P. Mycobacterium kansasii infection[M]. Treasure Island (FL): StatPearls Publishing, 2023.
|
[16] |
中华医学会放射学分会传染病放射学组, 中国医师协会放射医师分会感染影像专业委员会, 中国研究型医院学会感染与炎症放射专业委员会, 等. 肺结核影像诊断标准[J]. 新发传染病电子杂志, 2021, 6(1): 1-6. https://www.cnki.com.cn/Article/CJFDTOTAL-XFCR202101001.htm
|
[17] |
王玉香, 胡秋萌, 郑俊峰, 等. 堪萨斯分枝杆菌肺病与胞内分枝杆菌肺病临床特征及预后分析[J]. 结核与肺部疾病杂志, 2023, 4(6): 480-5. https://www.cnki.com.cn/Article/CJFDTOTAL-FBJK202306009.htm
|
[18] |
Wang PH, Pan SW, Wang SM, et al. The impact of nontuberculous Mycobacteria species on mortality in patients with nontuberculous mycobacterial lung disease[J]. Front Microbiol, 2022, 13: 909274. doi: 10.3389/fmicb.2022.909274
|
[19] |
Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases[J]. Am J Respir Crit Care Med, 2007, 175(4): 367-416. doi: 10.1164/rccm.200604-571ST
|
[20] |
Arend SM, de Palou EC, de Haas P, et al. Pneumonia caused by Mycobacterium kansasii in a series of patients without recognised immune defect[J]. Clin Microbiol Infect, 2004, 10(8): 738-48. doi: 10.1111/j.1469-0691.2004.00898.x
|
[21] |
肖海浩, 汤春梅, 潘育文, 等. 气管支气管结核患者咯血的临床分析[J]. 广东医学, 2021, 42(4): 400-3. https://www.cnki.com.cn/Article/CJFDTOTAL-GAYX202104007.htm
|
[22] |
廖志中, 文小检, 张孟婷, 等. 肺部CT表现对结核性咯血责任血管的预测价值[J]. 用放射学杂志, 2022, 38(7): 1092-5. doi: 10.3969/j.issn.1002-1671.2022.07.011
|
[23] |
楼海, 孙勤, 顾瑾, 等. 常见非结核分枝杆菌肺病的临床特征及药物敏感试验结果分析[J]. 中华结核和呼吸杂志, 2019, 42(12): 901-6. doi: 10.3760/cma.j.issn.1001-0939.2019.12.005
|
[24] |
中华医学会结核病学分会, 《中华结核和呼吸杂志》编辑委员会. γ-干扰素释放试验在中国应用的建议[J]. 中华结核和呼吸杂志, 2014, 37(10): 744-7. doi: 10.3760/cma.j.issn.1001-0939.2014.10.011
|
[25] |
Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)[J]. Thorax, 2017, 72(Suppl 2): ii1-ii64. doi: 10.1136/thoraxjnl-2017-210927
|
[26] |
高春景, 杨洋, 李星, 等. 40例堪萨斯分枝杆菌肺病的临床特征及药敏特点分析[J]. 临床肺科杂志, 2022, 27(1): 58-62. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFK202201013.htm
|
[27] |
Destefano MS, Shoen CM, Cynamon MH. Therapy for Mycobacterium kansasii infection: Beyond 2018[J]. Front Microbiol, 2018, 9: 2271. doi: 10.3389/fmicb.2018.02271
|
[28] |
任汝颜, 薛毅, 梁倩, 等. 堪萨斯分枝杆菌临床分离株对异烟肼敏感性差异机制研究[J]. 中国防痨杂志, 2023, 45(8): 728-33. https://www.cnki.com.cn/Article/CJFDTOTAL-ZFLZ202308002.htm
|
[29] |
Ismail NA, Omar SV, Joseph L, et al. Defining bedaquiline susceptibility, resistance, cross-resistance and associated genetic determinants: a retrospective cohort study[J]. EBioMedicine, 2018, 28: 136-42. doi: 10.1016/j.ebiom.2018.01.005
|
[30] |
Luo J, Yu X, Jiang G, et al. In vitro activity of clofazimine against nontuberculous mycobacteria isolated in Beijing, China[J]. Antimicrob Agents Chemother, 2018, 62(7): e00072-18.
|
[31] |
陈华, 方伟军, 胡锦兴, 等. 两种常见缓慢生长型非结核分枝杆菌肺病的胸部CT征象比较[J]. 新发传染病电子杂志, 2021, 6(4): 311-4. https://www.cnki.com.cn/Article/CJFDTOTAL-XFCR202104011.htm
|
[32] |
徐勇, 陆蓉容. 鸟分枝杆菌复合群肺病和堪萨斯分枝杆菌肺病临床特点的对比研究[J]. 中外医学研究, 2020, 18(29): 162-4. https://www.cnki.com.cn/Article/CJFDTOTAL-YJZY202029064.htm
|
[33] |
杨晴媛, 邢志珩, 秦中华, 等. 胞内分枝杆菌肺病CT特征: 与堪萨斯、脓肿/龟分枝杆菌肺病比较[J]. 中国医学影像技术, 2019, 35(6): 857-61. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201906021.htm
|
[34] |
Morimoto K, Maeda S, Yoshiyama T, et al. Clinico-microbiological characteristics of Mycobacterium kansasii pulmonary disease at a specialized mycobacteriosis hospital in tokyo, japan[J]. Kekkaku, 2015, 90(4): 453-6.
|
[35] |
Jung SS, Park HS, Kim JO, et al. Incidence and clinical predictors of endobronchial tuberculosis in patients with pulmonary tuberculosis[J]. Respirology, 2015, 20(3): 488-95. doi: 10.1111/resp.12474
|
[36] |
Luttmann KF, Starnes VR, Rostad K, et al. Pleural Effusion/Empyema with Mycobacterium kansasii[J]. Cureus, 2022, 14(1): e21300.
|
[37] |
周碧霞, 袁功玲, 曾令武, 等. 堪萨斯分枝杆菌肺病与肺结核空洞CT征象对比分析[J]. 结核与肺部疾病杂志, 2021, 2(2): 125-30. doi: 10.3969/j.issn.2096-8493.2021.02.007
|
[38] |
Kim TS, Koh WJ, Han J, et al. Hypothesis on the evolution of cavitary lesions in nontuberculous mycobacterial pulmonary infection: thin-section CT and histopathologic correlation[J]. AJR Am J Roentgenol, 2005, 184(4): 1247-52. doi: 10.2214/ajr.184.4.01841247
|